Stock AnalizCastle Biosciences Inc. CSTL
Medical Specialities · IPO 2019 · data as of November 13, 2026
Castle Biosciences Inc. (CSTL) is a healthcare company listed in the US with a market value of about $1.0B. In the twelve months to September 30, 2026 it had revenue of $377M and net income of -$23M, a net margin of -6.1%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 262.8, 5-year revenue growth of 41% a year, a 5-year average ROIC of -8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 80% below the current price.
Score: 1.4 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $377M | $344M | $332M | $220M | $137M | $94M | $63M | $52M | $23M |
| Net income | -$23M | -$24M | $18M | -$57M | -$67M | -$31M | -$10M | $5M | -$6M |
| Free cash flow | $4M | $28M | $37M | -$19M | -$47M | -$22M | $5M | $6M | -$13M |
| EPS (diluted) | $-0.76 | $-0.83 | $0.62 | $-2.14 | $-2.58 | $-1.24 | $-0.54 | $-0.21 | $-5.33 |
| Net margin | -6.1% | -7.0% | 5.5% | -26.2% | -49.0% | -33.3% | -16.4% | 10.2% | -27.9% |
| ROIC | — | -6.7% | 1.4% | -13.2% | -14.0% | -7.5% | -1.2% | 5.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $48.20, 43% above the current price; targets range from $40.00 to $60.00; the consensus rating is “Strong buy”; expected EPS is $-0.85 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Castle Biosciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 80% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Castle Biosciences pay a dividend?
Not currently.
Is Castle Biosciences a good stock to buy?
We do not give buy or sell advice. Castle Biosciences scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.